Hanahan & Weinberg (2011)
Hallmarks of cancer: the next generation. Cell 144:646โ674. doi:10.1016/j.cell.2011.02.013
View on DOIHow EVOS S1000 and EVOS M7000 fit cancer spatial-biology workflows โ peer-reviewed papers on tumour microenvironments, spatial transcriptomics and multiplex immunofluorescence.
Spatial biology keeps tissue context intact while measuring gene expression, protein location and cellโcell interactions. Cancer research especially needs this because the tumour microenvironment โ immune cells, stroma, blood vessels and hypoxic regions โ often determines drug response and outcome.
| Task | Recommended EVOS | Why |
|---|---|---|
| Multiplex IF on FFPE/fresh-frozen tumour sections | EVOS S1000 | Up to 9-plex spectral fluorescence, slide-based, high-resolution optical quality |
| Live tumour organoid / tumoroid time-lapse | EVOS M7000 | On-stage incubation, automated multi-well acquisition, Z-stacking |
| Pre-clinical validation of 3D cancer models | EVOS M7000 | Confluence, transfection and counting analysis plus fluorescence imaging |
| Budget entry into tissue fluorescence | EVOS M5000 | 4-colour LED fluorescence and transmitted light for thinner sections or 2D cultures |
Uses single-cell spatial transcriptomics to follow progression from ductal carcinoma in situ to invasive breast carcinoma, mapping tumour-immune neighbourhoods.
Read the paper on Nature Communications โ
High-resolution spatial transcriptomics of colorectal cancer immune microenvironments, revealing spatially organised immune cell states and their relation to tumour progression.
Read the paper on Nature Genetics โ
Multiplex immunofluorescence and image analysis map immune cell neighbourhoods in NSCLC, linking spatial organisation to clinical outcomes.
Read the paper on Nature Communications โ
Combines multiplexed immunofluorescence with metabolic imaging to explain why some NSCLC tumours respond to immune-checkpoint inhibitors while others do not.
Read the paper on Nature Communications โ
Presents a 3D multiplexed immunofluorescence pipeline that preserves whole-tissue architecture to profile cell states and immune niches across human tumours.
Read the paper on Nature Methods โ
Introduces a pathology-oriented multiplex imaging approach for integrative disease mapping across kidney and other tissues, emphasising protein location as a disease determinant.
Although organoid-focused, the signal-correction and segmentation pipeline applies to multi-layered cancer tumoroids and 3D tissue models.
For sections>10 ยตm or cleared organoids/tumoroids, use 2โ5 ยตm Z-steps. EVOS M7000 supports Z-stack acquisition for live 3D cultures; EVOS S1000 is designed for slide-based multiplex fluorescence imaging of tissue sections. Deeper whole-mount samples may still need light-sheet or confocal for best resolution.
Use EVOS S1000 mIF to confirm transcriptomics findings at the protein level on adjacent sections, then use EVOS M7000 live imaging to test perturbations in 3D models before returning to tissue.
Yes. The EVOS S1000 Spatial Imaging System is designed for multiplexed fluorescence imaging of tissue slides, supporting up to 9-plex spectral unmixing. It fits cancer spatial-biology workflows that need medium-plex immunofluorescence panels of tumour and immune markers on FFPE or fresh-frozen sections without the capital cost of a full spatial-omics platform.
The EVOS S1000 is a slide-based tissue imager for multiplex immunofluorescence on fixed tissue sections. The EVOS M7000 is an inverted automated microscope for live-cell and live-tissue assays, Z-stack time-lapse, multi-well plates and confluence analysis. In a cancer spatial-biology lab they complement each other: S1000 for tissue-section panels, M7000 for live 3D cultures and pre-tissue model validation.
No. The papers above are independent peer-reviewed cancer spatial-biology studies that used a range of spatial transcriptomics, multiplex immunofluorescence and imaging platforms. We map each workflow to the EVOS S1000 or EVOS M7000 specifications so UK labs can choose an appropriate Thermo Fisher imaging workflow.
Hallmarks of cancer: the next generation. Cell 144:646โ674. doi:10.1016/j.cell.2011.02.013
View on DOIOrganoids in cancer research. Nature Reviews Cancer 18:407โ418. doi:10.1038/s41568-018-0007-6
View on DOIA living biobank of breast cancer organoids captures disease heterogeneity. Cell 172:373โ386. doi:10.1016/j.cell.2017.11.010
View on DOIMolecular Biology of the Cell, 7th ed. W.W. Norton. doi:10.1201/9781003217356
View on DOIMapping molecular features within intact tumour tissue to study heterogeneity and microenvironment.
EVOS S1000 captures spatial fluorescence data; M7000 supports live-cell and 3D pre-processing.